123b-33bcCAR T-cells

123b-33bcCAR T-cells are a dual-specificity **chimeric antigen receptor T cell therapy** engineered to independently recognize and target both **CD123** and **CD33** antigens on malignant hematopoietic cells. This dual-targeting design enables robust and specific lysis of tumor populations expressing either or both antigens, including acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (B-ALL) patient-derived samples. The construct incorporates discrete receptor units, allowing each CAR to function independently, thus minimizing the risk of tumor antigen escape and broadening the targeting scope within heterogeneous leukemic populations. Functional studies demonstrate potent, antigen-specific cytotoxicity against leukemic cells, including primary tumor samples and leukemia stem cell compartments, with high tumor lysis rates at various effector-to-target ratios[1].